María Ángeles Sala

Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial

José Trigo, Vivek Subbiah, Benjamin Besse et al. · The Lancet Oncology · 2020 · 462 citations

Medicine, Oncology, Pharmacology +9

Customized Treatment in Non-Small-Cell Lung Cancer Based on EGFR Mutations and BRCA1 mRNA Expression

Rafael Rosell, Laia Perez‐Roca, José Javier Sánchez et al. · PLoS ONE · 2009 · 160 citations · Full text

Medicine, Oncology, Pharmacology +14

A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial

Ross A. Soo, Ji‐Youn Han, Urania Dafni et al. · Annals of Oncology · 2021 · 116 citations · Full text

Medicine, Oncology, Pharmacotherapy +10

Lung cancer in Spain: information from the Thoracic Tumors Registry (TTR study)

Mariano Provencio, Enric Carcereny, Delvys Rodríguez‐Abreu et al. · Translational Lung Cancer Research · 2019 · 93 citations · Full text

Medicine, Oncology, Cancer Epidemiology +14

Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study

Marta Martín-Richard, Bartomeu Massutí, Eva Margarita Pineda et al. · BMC Cancer · 2013 · 70 citations · Full text

Medicine, Oncology, Pharmacology +17